K. Rajesh Malik's Insider Trades & SAST Disclosures
K. Rajesh Malik's most recent trade in G1 Therapeutics Inc was a trade of 89,762 Common Stock done . Disclosure was reported to the exchange on Sept. 18, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern K. Rajesh Malik.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Sep 2024 | 89,762 | 87,450 (0%) | 0% | - | Common Stock | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | 18 Sep 2024 | 87,450 | 0 (0%) | 0% | - | Common Stock | ||
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Sep 2024 | 74,500 | 0 | - | - | Stock Option (right to buy) | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Sep 2024 | 57,333 | 0 | - | - | Stock Option (right to buy) | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Sep 2024 | 36,924 | 0 | - | - | Stock Option (right to buy) | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Sep 2024 | 35,700 | 0 | - | - | Stock Option (right to buy) | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2024 | 17,900 | 177,212 (0%) | 0% | - | Common Stock | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 2.51 per share. | 05 Jul 2024 | 2,475 | 159,312 (0%) | 0% | 2.5 | 6,207 | Common Stock |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.79 per share. | 13 May 2024 | 8,151 | 161,787 (0%) | 0% | 4.8 | 39,034 | Common Stock |
| G1 Therapeutics Inc | Malik Rajesh K. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 28,600 | 0 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.62 per share. | 12 Feb 2024 | 28,600 | 169,938 (0%) | 0% | 4.6 | 132,143 | Common Stock |
| G1 Therapeutics Inc | Rajesh Malik K. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 12 Feb 2024 | 28,600 | 198,538 (0%) | 0% | 0.3 | 8,580 | Common Stock |
| G1 Therapeutics Inc | K. Malik Rajesh | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 74,500 | 74,500 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Malik K. Rajesh | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 37,300 | 173,678 (0%) | 0% | 0 | Common Stock | |
| G1 Therapeutics Inc | Malik K. Rajesh | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.12 per share. | 03 Jan 2024 | 2,261 | 170,659 (0%) | 0% | 3.1 | 7,052 | Common Stock |
| G1 Therapeutics Inc | K. Rajesh Malik | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.12 per share. | 03 Jan 2024 | 758 | 172,920 (0%) | 0% | 3.1 | 2,364 | Common Stock |
| G1 Therapeutics Inc | Malik Rajesh K. | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 2.94 per share. | 03 Jan 2024 | 721 | 169,938 (0%) | 0% | 2.9 | 2,121 | Common Stock |
| POINT Biopharma Global Inc | Malik Rajesh K. | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Dec 2023 | 44,749 | 0 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | K. Malik Rajesh | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Dec 2023 | 25,614 | 0 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | K. Rajesh Malik | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Dec 2023 | 25,000 | 0 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | Malik Rajesh K. | Director | 26 Dec 2023 | 3,700 | 0 | - | - | Common Stock | ||
| G1 Therapeutics Inc | Malik Rajesh K. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 11 Dec 2023 | 21,439 | 157,817 (0%) | 0% | 0.4 | 8,361 | Common Stock |
| G1 Therapeutics Inc | Rajesh Malik K. | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.06 per share. | 11 Dec 2023 | 21,439 | 136,378 (0%) | 0% | 3.1 | 65,659 | Common Stock |
| G1 Therapeutics Inc | Malik K. Rajesh | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2023 | 21,439 | 0 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | K. Malik Rajesh | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 11 Dec 2023 | 12,400 | 148,778 (0%) | 0% | 0.3 | 3,720 | Common Stock |
| G1 Therapeutics Inc | Rajesh Malik K. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2023 | 12,400 | 28,600 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | K. Malik Rajesh | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.02 per share. | 11 Dec 2023 | 12,400 | 136,378 (0%) | 0% | 4.0 | 49,863 | Common Stock |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 2.45 per share. | 05 Jul 2023 | 1,361 | 136,378 (0%) | 0% | 2.5 | 3,339 | Common Stock |
| POINT Biopharma Global Inc | Rajesh K. Malik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 44,749 | 44,749 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 35,000 | 137,739 (0%) | 0% | 0 | Common Stock | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 35,700 | 35,700 | - | - | Stock Options (Right to buy) | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 17,900 | 105,107 (0%) | 0% | 0 | Common Stock | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.58 per share. | 03 Jan 2023 | 1,639 | 103,468 (0%) | 0% | 5.6 | 9,138 | Common Stock |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.41 per share. | 03 Jan 2023 | 729 | 102,739 (0%) | 0% | 5.4 | 3,942 | Common Stock |
| POINT Biopharma Global Inc | Rajesh K. Malik | Director | Purchase of securities on an exchange or from another person at price $ 6.66 per share. | 28 Nov 2022 | 3,700 | 3,700 | - | 6.7 | 24,642 | Common Stock |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.71 per share. | 13 Sep 2022 | 18,000 | 73,207 (0%) | 0% | 15.7 | 282,746 | Common Stock |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2022 | 18,000 | 21,439 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 13 Sep 2022 | 18,000 | 91,207 (0%) | 0% | 0.4 | 7,020 | Common Stock |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.17 per share. | 05 Jul 2022 | 648 | 73,207 (0%) | 0% | 5.2 | 3,351 | Common Stock |
| POINT Biopharma Global Inc | Rajesh K. Malik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 25,614 | 25,614 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 01 Feb 2022 | 10,000 | 73,855 (0%) | 0% | 0.3 | 3,000 | Common Stock |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2022 | 10,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 53,000 | 53,000 | - | - | Stock Options (Right to buy) | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 12,000 | 65,300 (0%) | 0% | 0 | Common Stock | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.61 per share. | 03 Jan 2022 | 1,445 | 63,855 (0%) | 0% | 10.6 | 15,334 | Common Stock |
| POINT Biopharma Global Inc | Rajesh K. Malik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jul 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2021 | 10,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 10 May 2021 | 10,000 | 53,300 (0%) | 0% | 0.3 | 3,000 | Common Stock |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.07 per share. | 22 Apr 2021 | 15,000 | 43,300 (0%) | 0% | 22.1 | 331,100 | Common Stock |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 22 Apr 2021 | 15,000 | 58,300 (0%) | 0% | 0.4 | 5,850 | Common Stock |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Apr 2021 | 15,000 | 39,439 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.94 per share. | 23 Mar 2021 | 15,000 | 43,300 (0%) | 0% | 21.9 | 329,060 | Common Stock |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 23 Mar 2021 | 15,000 | 58,300 (0%) | 0% | 0.4 | 5,850 | Common Stock |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Mar 2021 | 15,000 | 54,439 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.95 per share. | 02 Mar 2021 | 15,000 | 43,300 (0%) | 0% | 22.9 | 344,192 | Common Stock |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2021 | 10,405 | 69,439 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 02 Mar 2021 | 10,405 | 53,705 (0%) | 0% | 0.4 | 4,058 | Common Stock |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.17 per share. | 02 Mar 2021 | 4,595 | 58,300 (0%) | 0% | 4.2 | 19,161 | Common Stock |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2021 | 4,595 | 36,924 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2021 | 3,100 | 79,844 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 27 Jan 2021 | 3,100 | 43,300 (0%) | 0% | 0.4 | 1,209 | Common Stock |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.64 per share. | 22 Jan 2021 | 15,000 | 40,200 (0%) | 0% | 20.6 | 309,591 | Common Stock |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2021 | 15,000 | 41,519 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.17 per share. | 22 Jan 2021 | 15,000 | 55,200 (0%) | 0% | 4.2 | 62,550 | Common Stock |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 58,000 | 58,000 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Rajesh K. Malik | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 11,000 | 40,200 (0%) | 0% | 0 | Common Stock | |
| G1 Therapeutics Inc | Rajesh K. Malik | Ch. Medical Officer & SVP R&D | Sale of securities on an exchange or to another person at price $ 20.06 per share. | 10 Dec 2020 | 9,000 | 29,200 (0%) | 0% | 20.1 | 180,550 | Common Stock |
| G1 Therapeutics Inc | Rajesh K. Malik | Ch. Medical Officer & SVP R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2020 | 9,000 | 56,519 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Rajesh K. Malik | Ch. Medical Officer & SVP R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.17 per share. | 10 Dec 2020 | 9,000 | 38,200 (0%) | 0% | 4.2 | 37,530 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges